ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ben Lamm's Astromech Secures $30 Million to Advance AI-Biotechnology Innovation

Funding underscores strong investor interest in AI applications for life sciences.

AUSTIN, TX / ACCESS Newswire / September 23, 2025 / Entrepreneur Ben Lamm, co-founder of Colossal Biosciences, has announced the successful close of a $30 million funding round for his new company, Astromech, highlighting growing investor confidence in the convergence of artificial intelligence and biotechnology.

Astromech is incorporated in Delaware and is currently operating in stealth mode. The company is developing proprietary AI technologies aimed at advancing research and development in biotechnology. Lamm is partnering with George Church, a Harvard researcher with deep expertise in genetics and synthetic biology, to build both the scientific and operational foundation of the venture.

Astromech's funding round places the company among well-capitalized early-stage AI startups, providing resources for technology development and business operations. The raise reflects a broader trend in which venture capital firms are showing increased interest in startups applying artificial intelligence to biological research challenges, pharmaceutical development, and healthcare applications.

Lamm's background with Colossal Biosciences-which focuses on de-extinction and cutting-edge genetic science-has provided added credibility with investors evaluating opportunities in the emerging AI-biotech sector.

About Astromech

Astromech is an artificial intelligence company focused on the application of advanced computational technologies to biotechnology and life sciences research. Incorporated in Delaware and currently operating in stealth mode, the company is developing proprietary platforms designed to accelerate progress in genetic research, pharmaceutical development, and related fields.

About Ben Lamm

Ben Lamm is a serial technology entrepreneur and the co-founder of Colossal Biosciences, a biotechnology company focused on de-extinction and genetic innovation. Lamm specializes in launching and scaling technology ventures at the intersection of science and advanced computing.

Contact:
Elizabeth Lodge
info@astromech.com

SOURCE: Astromech



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.